2025-524178-40-00CompletedPhase 1
A study to learn more about how safe nurandociguat is and how it affects the way the body processes rosuvastatin and dabigatran in healthy adults
Source: EU CTIS (euclinicaltrials.eu) · Last updated 24 Mar 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 16 Jan 2026
- Start date
- 8 Apr 2026
- Lead sponsor
- Bayer AG
- EU CT number
- 2025-524178-40-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 40
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CRS Clinical Research Services Mannheim GmbH | Mannheim | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.